Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2023-04-26 AGM Information
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
La Sociedad anuncia la convocatoria de la Junta General Ordinaria de Accionistas y remite propuestas de acuerdos.
AGM Information Classification · 99% confidence The document is an official communication to the 'Comisión Nacional del Mercado de Valores' (Spanish securities market regulator) announcing the calling of a 'Junta General Ordinaria de Accionistas' (Annual General Meeting of Shareholders). It details the date, location, and the full 'ORDEN DEL DÍA' (Agenda), which includes voting on annual accounts, management reports, director re-elections, and other corporate matters. This type of document, which formally announces and provides the materials/agenda for an AGM, is best classified as related to the Annual General Meeting. Since the document itself is the announcement/convocation and not the presentation materials (AGM-R) or the proxy solicitation materials (PSI), and it is a formal regulatory filing announcing a key shareholder event, it aligns most closely with the purpose of an AGM announcement, which is often covered under general shareholder meeting documentation. Given the options, 'AGM-R' (AGM Information) is the most specific fit for the core subject matter, although it is the *convocation* for the AGM rather than the presentation itself. However, since the agenda covers standard AGM items, and there isn't a specific 'AGM-Call' code, AGM-R is the closest thematic match for the event being organized. It is not a DEF 14A (Remuneration is only one item), nor is it a 10-K (Annual Report) or an ER (Earnings Release). It is the formal notice of the meeting.
2023-04-26 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is titled "MODELO DE NOTIFICACIÓN DE LAS OPERACIONES DE LAS PERSONAS CON RESPONSABILIDADES DE DIRECCIÓN Y DE LAS PERSONAS ESTRECHAMENTE VINCULADAS CON ELLAS" (Standard Form for Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with Them). This form explicitly details transactions (Compra/Buy) made by a director ('CONSEJERA') of the issuer (PHARMA MAR, S.A.). This directly corresponds to the definition of Director's Dealing, which covers reports of personal share transactions by company directors and executives (insider trades). The corresponding code is DIRS.
2023-04-24 Spanish
La Comisión Ejecutiva de Pharma Mar, S.A. ha decidido la ejecución del Plan de Entrega Gratuita de Acciones aprobado por acuerdo de su Junta General Ordinaria de fecha 29 de junio de 2022.
Share Issue/Capital Change Classification · 95% confidence The document is a formal notification ('OTRA INFORMACIÓN RELEVANTE') addressed to the Spanish National Securities Market Commission (Comisión Nacional del Mercado de Valores - CNMV). It details the execution of a free share delivery plan previously approved by the Shareholders' General Meeting. This plan involves issuing shares to employees and executives as an incentive, specifying conditions like lock-up periods and forfeiture clauses. This action directly relates to changes in the company's capital structure, specifically the issuance of shares as part of an employee incentive scheme, which falls under financing activities or capital structure changes. While it involves shares, it is not a standard buyback (POS) but rather a capital allocation/incentive plan. The most fitting category is Capital/Financing Update (CAP), as it describes the execution of a plan that changes the capital structure via share issuance to employees, distinct from a general share issue announcement (SHA) or a buyback (POS).
2023-04-17 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is titled "MODELO DE NOTIFICACIÓN DE LAS OPERACIONES DE LAS PERSONAS CON RESPONSABILIDADES DE DIRECCIÓN Y DE LAS PERSONAS ESTRECHAMENTE VINCULADAS CON ELLAS" (Standard Form for Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with Them). This form explicitly details transactions (Compra/Buy) in financial instruments (Acción/Share) conducted by a director ('CONSEJERA'). This directly corresponds to the definition of Director's Dealing, which covers reports of personal share transactions by company directors and executives (insider trades). The corresponding code is DIRS.
2023-04-17 Spanish
Axesor mantiene la calificación crediticia a largo plazo de Pharma Mar.
Capital/Financing Update Classification · 99% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator. It is dated April 11, 2023, and is titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). The content announces that the rating agency AXESOR has maintained Pharma Mar, S.A.'s long-term credit rating at 'BB+' with a stable outlook. This type of announcement, which relays external credit rating information to the market regulator, is a general regulatory disclosure that does not fit the specific categories like Earnings Release (ER), Annual Report (10-K), or Director's Dealing (DIRS). Given its nature as a mandatory disclosure of material, non-specific financial news to the regulator, the most appropriate fallback category is Regulatory Filings (RNS). The document length is very short (678 chars), suggesting it is an announcement rather than a full report.
2023-04-11 Spanish
La Sociedad remite detalle de las operaciones del Contrato de Liquidez comprendidas entre el 01/01/2023 y el 31/03/2023
Transaction in Own Shares Classification · 95% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator. The title is 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) and the subject is 'Operaciones trimestrales contrato de liquidez' (Quarterly operations of the liquidity contract). It details the buying and selling of company shares under a liquidity agreement for the first quarter of 2023 (January 1 to March 31, 2023). This type of mandatory disclosure regarding insider/market operations, specifically related to share liquidity contracts, is a routine regulatory filing in Spain. Since it is a specific regulatory disclosure that doesn't fit perfectly into the main financial reports (10-K, IR) or specific event announcements (DIV, MANG), it falls best under the general 'Regulatory Filings' category (RNS) or potentially a specific insider/share transaction category. Given the context of mandatory reporting of liquidity contract activity to the regulator, RNS (Regulatory Filings) is the most appropriate general classification for non-standard, mandatory disclosures, although 'POS' (Transaction in Own Shares) is related, RNS covers the mandatory reporting aspect better here. However, since the content is exclusively about the company's own share transactions (buying and selling under a liquidity contract), 'POS' (Transaction in Own Shares) is a more specific fit than the general 'RNS' fallback, as it details the transactions themselves. I will classify it as POS.
2023-04-10 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.